Systemic treatment for metastatic prostate cancer

The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...

Descripción completa

Detalles Bibliográficos
Autor principal: Gravis, Gwenaelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488732/
https://www.ncbi.nlm.nih.gov/pubmed/31061802
http://dx.doi.org/10.1016/j.ajur.2019.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488732/
https://www.ncbi.nlm.nih.gov/pubmed/31061802
http://dx.doi.org/10.1016/j.ajur.2019.02.002

Ejemplares similares